Trial Profile
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel in Healthy Subjects Aged 9 to 60 Years in the Philippines
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs CYD TDV (Primary) ; DTaP vaccine (Primary)
- Indications Dengue; Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors Sanofi Pasteur
- 10 Jun 2021 Primary endpoint has been met. (Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants) , according to Results published in the Pediatric Infectious Disease Journal
- 10 Jun 2021 Primary endpoint has been met. (Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants) , according to Results published in the Pediatric Infectious Disease Journal
- 10 Jun 2021 Primary endpoint has been met. (Geometric Mean Concentrations of Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) 28 Days After Dose of Tdap Vaccine in Previously Dengue Immune Participants) , according to Results published in the Pediatric Infectious Disease Journal